Eisai Co., Ltd. (ESALF)
OTCMKTS
· Delayed Price · Currency is USD
35.98
-2.52 (-6.55%)
Sep 25, 2024, 9:30 AM EDT
Eisai Employees
Eisai had 11,067 employees as of March 31, 2024. The number of employees decreased by 9 or -0.08% compared to the previous year.
Employees
11,067
Change (1Y)
-9
Growth (1Y)
-0.08%
Revenue / Employee
$412,202
Profits / Employee
$18,338
Market Cap
10.85B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Sandoz Group AG | 22,633 |
| Telix Pharmaceuticals Limited | 234 |
| Elekta AB (publ) | 4,718 |
| Ryman Healthcare Limited | 7,700 |
| Verano Holdings Corp. | 3,900 |
| Medexus Pharmaceuticals Inc. | 82 |
Eisai News
- 12 days ago - Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer - Seeking Alpha
- 12 days ago - KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma - Benzinga
- 17 days ago - Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges - Benzinga
- 18 days ago - Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment - CNBC
- 5 weeks ago - Biogen, Eisai new Alzheimer’s drug considered too costly in Britain - Seeking Alpha
- 5 weeks ago - Biogen/Eisai’s Alzheimer's drug wins marketing authorization in Great Britain - Seeking Alpha
- 5 weeks ago - UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug - Reuters
- 5 weeks ago - Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED - Seeking Alpha